Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ACP3 | P15309 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 4/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5159946 | 0.95 | KIF11 (0.40) | PTGS2OPRK1KIF11PTGS1OPRM1 | |
| SCHEMBL5158192 | 0.86 | PTGS2 (0.36) | PTGS2SLC6A4HRH3ALDH1A1 | |
| SCHEMBL5159848 | 0.85 | MEN1 (0.39) | PTGS2PTGS1SLC6A4TSHR | |
| SCHEMBL5160157 | 0.82 | SLC6A3 (0.38) | PTGS2PTGS1OPRM1SLC6A4HRH3 | |
| SCHEMBL5157968 | 0.77 | MEN1 (0.32) | PTGS2OPRK1 | |
| SCHEMBL5158439 | 0.75 | CHRNB4 (0.41) | OPRK1SLC6A4ACP3SLC6A9ALDH1A1 | |
| SCHEMBL5160367 | 0.72 | CHRNA7 (0.33) | ALDH1A1TSHR | |
| SCHEMBL5158176 | 0.72 | NAAA (0.39) | SLC6A4 | |
| SCHEMBL5160197 | 0.71 | OPRK1 (0.45) | OPRK1OPRM1OPRL1SLC6A4ACP3 | |
| Hydrochloric Acid SCHEMBL5160468 | 0.70 | OPRK1 (0.45) | OPRK1OPRM1OPRL1SLC6A4ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406857-B1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARYL-BUT-2-ENYLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2007-02-21 | — | — | EP | claimed |
| US-7064236-B2 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2006-06-20 | — | — | US | claimed |
| US-20040171615-A1 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2004-09-02 | — | — | US | claimed |
| EP-1406857-B1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARYL-BUT-2-ENYLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2007-02-21 | — | — | EP | disclosed |
| US-7064236-B2 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2006-06-20 | — | — | US | disclosed |
| US-20040171615-A1 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| EP-1406857-A1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARY-BUT-2-ENYLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004452-A1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARY-BUT-2-ENYLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171615-A1 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | ADRB3, BRD4, NAT1 | PTGS2 891/4885OPRK1 91/4885KIF11 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.